Viking Therapeutics: VK3019's Phase 1 Launch Ignites M&A Speculation and Diversifies Obesity Pipeline

Related Articles

Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market

6 months ago

What's Driving Viking (VIK) Stock Higher Today

4 months ago

Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise

3 months ago

AI's Profit Paradox: Navigating the Next Phase of Tech Investment

7 months ago

Category

You may also like

Stock News•1 week ago

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

Viking Therapeutics reported positive topline maintenance results for VK2735, with 22% placebo-adjusted weight loss at week 33 on 17.5 mg weekly dosing and no plateau. The data support monthly and eve...

GLP

Share

Stock News•2 months ago

Viking Therapeutics: Still Cheap, But Watch Double Top

Viking Therapeutics' GLP-1 pipeline advances with Phase 3 trials and oral formulation development. Consensus analyst price target of $92.58 implies upside, while biotech M&A activity highlights potent...

VKTX

Share

Stock News•2 months ago

Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?

Viking Therapeutics (VKTX) is seeing renewed buyout speculation as its obesity pipeline expands ahead of upcoming VK2735 data, boosting its strategic appeal.

VKTX

Share